| Univariate | Multivariate | ||
---|---|---|---|---|
Variables | Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value |
Age, ≥ 65 years | 1.47 (1.01–2.14) | 0.041 | 1.46 (0.99–2.15) | 0.056 |
Sex, men | 1.02 (0.68–1.57) | 0.941 |  |  |
Smoking, ever-smoker | 1.27 (0.84–1.96) | 0.257 |  |  |
ECOG-PS* | Â | Â | Â | Â |
 0 vs. 1 | 0.71 (0.47–1.09) | 0.114 | 0.98 (0.63–1.55) | 0.928 |
 0 vs. ≥ 2 | 0.34 (0.18–0.71) | 0.006 | 0.69 (0.34–1.53) | 0.340 |
 1 vs. ≥ 2 | 0.48 (0.24–1.03) | 0.059 | 0.70 (0.35–1.54) | 0.358 |
Charlson comorbidity index* | Â | Â | Â | Â |
 0 vs. 1 | 1.28 (0.83–2.05) | 0.271 | ||
 0 vs. ≥ 2 | 0.79 (0.47–1.14) | 0.407 | ||
 1 vs. ≥ 2 | 0.62 (0.33–1.18) | 0.139 | ||
GNRI, ≥ 92 | 0.28 (0.18–0.46) | < 0.001 | 0.35 (0.21–0.58) | < 0.001 |
Pathology, squamous cell (vs. non-squamous) | 1.20 (0.79–1.79) | 0.390 |  |  |
Stage, IIIb (vs. IV/ recurrent) | 0.85 (0.44–1.47) | 0.575 |  |  |
Platinum agents, cisplatin (vs. carboplatin) | 0.59 (0.35–0.95) | 0.029 | 0.64 (0.37–1.06) | 0.086 |
Non-platinum agents* | Â | Â | Â | Â |
 Pemetrexed vs. taxane | 0.62 (0.41–0.95) | 0.028 | 0.85 (0.54–1.37) | 0.509 |
 Pemetrexed vs. others | 0.58 (0.35–0.98) | 0.042 | 0.79 (0.45–1.40) | 0.408 |
 Taxane vs. others | 0.93 (0.57–1.55) | 0.781 | 0.92 (0.55–1.56) | 0.749 |
Treatment year, 2011–2020 (vs. 2000–2010) | 0.56 (0.39–0.84) | 0.005 | 0.65 (0.42–1.01) | 0.053 |